{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-059393","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2026-05-12T20:11:00+00:00","discovered_at":"2026-05-12T20:12:00.537372+00:00","generated_at":"2026-05-12T20:58:19.521064+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%","bullets":["Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.","Net loss $12.3M vs $11.3M prior year; operating loss $10.5M.","Gross margin 65.7% (down from 67.6%) on higher excess/obsolete inventory charge.","Reiterated FY2026 revenue growth at least 8% over FY2025; Q2 2026 expected ~$20.0M.","U.S. commercial launch of OviTex LTR (April 1) and board refreshment effective June 9, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-059393","json":"https://secwatch.observer/filing/0001104659-26-059393.json","markdown":"https://secwatch.observer/filing/0001104659-26-059393.md","text":"https://secwatch.observer/filing/0001104659-26-059393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/0001104659-26-059393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/tm2614218d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:58:19.521064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6bd6ebcff41a6f15ebcfe86818686a4da25b82b","claim":"TELA Bio, Inc. reported first quarter ended March 31, 2026 results: revenue $19.1 million, net income Net loss was $12.3 million. Guidance reaffirmed.","evidence_excerpt":"at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed at planned 2026 levels; · Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; · Accelerated European revenue growth to 41% over the prior year period, with continued","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926059393/0001104659-26-059393-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$19.1 million"},{"label":"Net income","value":"Net loss was $12.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}